IFNB1 and depressive symptom measurement: The first demonstration of a causal link between inflammation and subsequent onset of depression comes from the initial treatment trials using IFN in patients with specific infections or IFN-β in multiple sclerosis with depressive symptoms and suicidal behavior; according to these studies, depressive symptoms may emerge approximately one month after the first administration of this medication [57,58].